Expression of CREBBP and EP300 Associated With Tumor Volume in Patients With Grade-3 Glioma: A Retrospective Analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated CREBBP and EP300 mRNA levels correlate with larger glioma size. Inhibiting these proteins may enhance anti-tumor immunity for effective glioma treatment.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Glioma treatment decisions rely on predictive data, often limited.
- Cyclic adenosine monophosphate (cAMP)-response element binding protein (CREBBP) and E1A binding protein p300 (EP300) are implicated in various cancers.
Purpose Of The Study
- To investigate the mRNA expression of CREBBP and EP300 in grade-3 glioma.
- To explore the relationship between CREBBP/EP300 expression and glioma characteristics.
Main Methods
- Retrospective analysis of mRNA expression in 17 grade-3 glioma patients.
- SYBR Green real-time PCR for CREBBP and EP300 mRNA quantification.
- Univariate analyses correlating gene expression with clinical and histological data.
Main Results
- CREBBP and EP300 mRNA levels were significantly upregulated in larger gliomas (P < .05).
- Increased CREBBP expression correlated with higher cell density and heterogeneity.
- Complement 3 and 4 levels were downregulated in larger tumors (P < .05).
Conclusions
- Higher CREBBP and EP300 expression is associated with increased glioma volume.
- Inhibiting CREBBP/EP300 may boost anti-tumor immunity for potential therapeutic strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.